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Abstract 
Background and Aims 
It is difficult to determine the different stages of non-alcoholic fatty liver disease without the use of invasive 
liver biopsy. In this study we investigated five non-invasive biomarkers used previously to detect hepatic 
fibrosis and determined the level of agreement between them in order to inform future research. 
Methods 
In the Edinburgh Type 2 Diabetes Study, a population-based cohort aged 60-74 years with type 2 diabetes, 
831 participants underwent ultrasound assessment for fatty liver and had serum aspartate aminotransferase 
to alanine aminotransferase ratio (AST/ALT), aspartate to platelet ratio index (APRI), European Liver 
Fibrosis panel (ELF), Fibrosis-4 Score (FIB4) and liver stiffness measurement (LSM) measured. 
Results 
Literature based cut-offs yielded marked differences in the proportions of the cohort with probable liver 
fibrosis in the full cohort. Agreement between the top 5% of the distribution for each biomarker pair was 
poor. APRI and FIB4 had the best positive agreement at 76.4%, but agreement for all of the other serum 
biomarker pairs was between 18% and 34%. Agreement with LSM was poor (9% to 16%). 
Conclusions 
We found poor correlation between the five biomarkers of liver fibrosis studied. Using the top 5% of each 
biomarker resulted in good agreement on the absence of advanced liver disease but poor agreement on the 
presence of advanced disease. Further work is required to validate these markers against liver biopsy and to 
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determine their predictive value for clinical liver-related endpoints, in a range of different low and high risk 
population groups.   
Word count: 238 
Key words: hepatic fibrosis, non-invasive biomarker tests, non-alcoholic fatty liver disease, type 2 diabetes 
mellitus.
5 
 
Introduction 
Liver dysfunction in people with type 2 diabetes mellitus is thought to be mainly caused by non-alcoholic 
fatty liver disease (NAFLD). The earliest stage of NAFLD is simple steatosis but this can progress to non-
alcoholic steatohepatitis (NASH) and ultimately to hepatic fibrosis, cirrhosis and the long term 
complications of chronic liver disease (CLD) such as hepatocellular carcinoma.  The prevalence of NAFLD 
is thought to be higher in type 2 diabetes than in the general population[1-4]. Research focusing on the 
identification of fatty liver using ultrasound suggests a prevalence of around 34% in the general 
population[1] ; in type 2 diabetes our own group found the prevalence to be 42.6%[2] and this figure may 
rise to 70% in more selected sub-populations of diabetes [3, 4]. The prevalence of NASH and NASH-related 
fibrosis is much harder to determine as currently the only widely accepted diagnostic method is liver biopsy.  
However, it is difficult to justify performing liver biopsy to determine the severity of liver disease in 
community based subjects, including volunteers in  research settings for two key reasons i) there is 
considerable variability in sampling and histopathological interpretation due to the small volume of tissue 
sampled (typically 0.002% of the liver)[5] and subjective semi-quantitative scoring systems[6-8], and ii) 
biopsy is associated with an adverse outcome profile including pain, bleeding and rarely death[9-12]. Thus, 
there is considerable interest in the adoption of validated non-invasive markers of fibrosis into clinical 
practice. In the few biopsy studies of populations with type 2 diabetes, the prevalence of advanced fibrosis 
in those with NAFLD was 7-12%[13-15]. 
Non-invasive markers have been extensively validated in secondary care for the diagnosis of hepatic fibrosis 
either for specific underlying pathologies (e.g. the NAFLD Fibrosis Score, NFS) or with varying disease 
specific cut-offs. There are three broad groups of biomarkers: single markers, combination marker panels 
and imaging. Increasing numbers of scales and scores are being developed, with most studies reporting 
acceptable diagnostic accuracy (AUC>0.7) for individual methods in diagnosing the presence of hepatic 
fibrosis in NAFLD. However, their reliability and utility in identifying undiagnosed liver fibrosis in wider 
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clinical practice and in research settings is yet to be determined given the limited studies in primary care[16, 
17].  Our group has previously shown[18] that the utility of many simple marker panels (BAAT score, 
BARD score, NFS) is limited in a population with type 2 diabetes by the inclusion of age, body mass index 
(BMI) and diabetes and led to over-estimation of the prevalence of fibrosis and high levels of indeterminate 
results.  
In this study we investigated five biomarkers used previously to detect hepatic fibrosis in clinical 
populations with NAFLD. We aimed to determine the level of agreement between these biomarkers, in a 
large, representative, well-phenotyped population of people with type 2 diabetes mellitus (the Edinburgh 
Type 2 Diabetes Study, ET2DS).  
7 
 
Patients and Methods 
Study population 
Full methods of the ET2DS have been published previously[19].  In brief, patients aged 60 to 75 years were 
selected at random from the Lothian Diabetes Register (LDR), a comprehensive register of patients with 
diabetes living in Lothian, Scotland.  1066 patients were recruited and attended a baseline clinic for physical 
examination.  Study recruits  have been shown previously to be largely representative of all those randomly 
selected to participate (n=5454) and therefore of the target population of older men and women with type 2 
diabetes living in the general population[20].   Participants who were able and willing (n=939) attended a 
liver assessment 1 year after baseline, including liver ultrasound scanning (USS)[21].   Subjects who were 
still living were invited to a further detailed assessment approximately four years after recruitment; these 
subjects (n=831) form the study population for the current analysis.  
Ethical approval was obtained from the Lothian Research Ethics Committee and all subjects gave written 
informed consent. 
Clinical examination and liver assessment  
Clinical examination at the year 1 liver assessment and year 4 follow-up was similar to that performed in 
earlier phases of the study, described in detail previously[19]. In brief, patients underwent physical 
examination (including height and weight measurements); venepuncture; self-administered questionnaire 
(including alcohol consumption) and liver imaging (including USS and transient elastography (TE)). Plasma  
glucose, HbA1c, platelets and liver enzymes (including alanine aminotransferase (ALT), aspartate 
aminotransferase (AST)) and albumin were measured on a fasting blood sample using a Vitros Fusion 
chemistry system (Ortho Clinical Diagnostics, Bucks, UK).  European Liver Fibrosis (ELF) panel - 
comprising hyaluronic acid (HA), aminoterminal peptide of pro-collagen III (P3NP) and tissue inhibitor of 
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matrix metalloproteinase 1 (TIMP1) - was measured using the ADVIA Centaur immunoassay system 
(Siemens Healthcare Diagnostics Inc, New York, USA) on serum stored at -80oC. USS was performed using 
a Sonoline Elegra Ultrasound Imaging System (Sieman's Medical Systems Inc, Washington, USA), software 
version 6, using a 3.5 MHz transducer. A phantom (411 LE 0.5, GAMMEX rmi Ltd, Nottingham, UK) as 
described and validated previously using magnetic resonance spectroscopy[21] , hepatic steatosis was 
graded as present or absent based on standard criteria.   
One dimensional TE was performed using a FibroScan (Echosens, Paris, France) machine at the year 4 
follow-up visit only. A single operator was formally trained by Echosens personnel prior to commencement 
of the study. Initial ultrasound assessment allowed measurement of the skin-capsule distance (SCD). For 
SCDs <2.5cm the M probe was used, for SCDs ≥2.5cm the XL probe was used in accordance with 
recommended standard Fibroscan operating procedures.  The TE probe was placed in an intercostal space 
overlying the liver with the patient in the supine position. Using ultrasound to guide positioning, an area of 
the liver that was at least 6cm deep and free from large vessels was selected for investigation. The area 
measured was between 25mm-65mm below the surface of the skin for the M probe and 35mm-75mm for the 
XL probe. The operator aimed to obtain ten valid liver stiffness measurements (LSM) with a success rate of 
at least 60% and IQR <30% of the final (median) result.  All scans were undertaken in the fasting state 
(minimum 4 hours). Every six months the probes were serviced and calibrated. 
Any patient with plasma liver enzymes above the upper reference limit, any abnormality on liver USS 
(including steatosis) or LSM > 8kPa underwent a liver screen including viral serology, alpha-feto protein, 
ferritin, autoantibodies, immunoglobulins, caeruloplasmin and 1-antitrypsin.  In addition, pre-diagnosed 
liver disease was identified from NHS National Services Scotland, Information Services Division data 
linkage to SMR01 general and acute inpatient discharge records and from patient self-report questionnaires 
on prior health conditions. Any liver disease identified from linkage and the patient questionnaire was 
confirmed using individual patient medical records and patients with confirmed pre-diagnosed liver disease 
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(chronic viral hepatitis, CVH, haemochromatosis and primary biliary cirrhosis, PBC) were excluded from 
the final analyses. 
Data analysis 
The five biomarkers/panels evaluated in this investigation were derived as follows: 
 Aspartate aminotransferase to alanine aminotransferase ratio (AST/ALT) calculated as AST(U/L) / 
ALT(U/L). 
 Aspartate to platelet ratio index (APRI) calculated as [AST(U/L) / upper limit normal] / 
platelets(x109/L)]x100[22]. 
 European Liver Fibrosis panel (ELF) calculated as 2.588 + (ln(HA)*(ln(P3NP)*0.775) + 
(ln(TIMP1)*0.494)[23]. 
 Fibrosis-4 Score (FIB4) calculated as [age(years) x AST(U/L)] / [platelets(x109/L) x √AST(U/L)][24]. 
 Liver stiffness measurement in kilopascals (kPa) expressed as the median TE value from at least ten 
valid measurements. 
Absolute change in serum biomarker was defined as the change between the year 1 liver assessment and 
year 4 follow-up. Serum biomarker change was also defined categorically as: increased (increase of >5% of 
liver assessment value); decreased (decrease of >5% of liver assessment value); and stayed the same 
(absolute change within 5% of liver assessment value). 
NAFLD was defined as the presence of hepatic steatosis on USS without alcohol excess or use of 
hepatotoxic medication and a negative liver screen. Alcohol excess was defined according to established 
criteria as alcohol intake >14 units/week (female) or >21 units/week (male)[25], or participant self-report of 
current/previous alcohol excess[26]. Use of hepatotoxic medication included the use of (non-topical) 
glucocorticoids for >2 weeks, isoniazid, methotrexate, amiodarone, or tamoxifen within the 6 months prior 
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to USS[3, 26]. Clinically significant positive immunology titres were defined as ASmA titre >1:160 or 
AMA titre >1:40[26, 27]. 
All patients with data available for APRI, AST/ALT ratio, ELF, and FIB4 were included in the analysis. All 
continuous variables were assessed for approximation to the normal distribution with APRI and FIB4 
showing a skewed distribution. Correlation between biomarkers was analysed after standardisation to Z-
scores, and adjusted for age and sex. Cronbach’s alpha was used to examine the inter biomarker agreement 
(using standardised Z-scores). Student’s t-test or the Mann-Whitney U test were used to compare means and 
Chi-squared test to compare proportions.  
Validated cut-offs to reliably exclude advanced fibrosis (≥ metavir F3) in NAFLD were determined from the 
literature aiming to achieve negative predictive values (NPVs) 90-95%: APRI=1.0, specificity (spec.) 89%, 
NPV 84%[22, 28]; AST/ALT=1.0, spec. 90%, NPV 89%[28]; ELF=10.358, spec. 94%, NPV 90%[23]; 
FIB4=1.30, spec. 65%, NPV 95%[24, 28]; and LSM=8.7, spec. 83.2%, NPV 94.6%[29].  However, since 
these threshold levels cannot reliably be extrapolated from the predominantly secondary care settings in 
which they were validated to a general population setting, we also assessed agreement between biomarkers 
using the same highest percentile across all biomarker panels.  Prior studies suggest that the prevalence of 
advanced fibrosis in type 2 diabetes patients attending outpatient clinics is at least 2-6% in all patients and 7-
12% in those with NAFLD[13-15]. As a result we estimated that the underlying prevalence of significant 
hepatic fibrosis in the whole ET2DS cohort might be in the region of 5% and around 10% in those with 
NAFLD. We therefore compared the top 5% (and 10%) of scores for each biomarker for agreement in the 
entire cohort (and in those with NAFLD respectively).  Individual 2x2 tables were calculated for the 
absence/presence of probable fibrosis (based on percentiles) for each pair of biomarkers. Due to the 
difficulties interpreting markers of total agreement[30] (e.g. kappa statistics), we calculated positive 
agreement (agreement on the presence of fibrosis by both biomarkers) and negative agreement (agreement 
on the absence of fibrosis by both biomarkers)[31]. 
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Correlation between absolute changes in serum biomarkers (i.e. between year 1 and year 4) was analysed 
after standardisation to Z-scores, and adjusted for age and sex. Categorical change in biomarker was 
analysed using the Chi-squared test to compare proportions. 
Analysis was undertaken on both the whole population without pre-diagnosed liver disease and additionally 
in those with NAFLD (defined as the presence of hepatic steatosis on USS without alcohol excess, use of 
hepatotoxic medication or abnormal liver screen).  
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Results 
Participants 
831 participants (78% of the original cohort) attended the 4-year follow-up clinic. There were no significant 
differences between attenders at baseline and at the 4-year visit (Table 1). Of the subjects that did not attend 
the 4-year clinic (n=235), nine had withdrawn from the study, 14 were un-contactable, 124 were unable or 
unwilling to attend and 88 had died. Eleven patients were excluded from the analysis due to pre-diagnosed 
liver disease. 
767 participants had a complete biomarker dataset (excluding LSM) available for analysis. Of these, valid 
LSM was reported for n=650. Missing plasma and serum markers were missing at random. LSM was 
missing in 117 participants (15.3%) due to failure to obtain valid readings. Patients with missing LSM were 
significantly more obese, with poorer glucose control and more severe markers of liver dysfunction (Table 
2).  There were 282 (36.8%) participants fulfilling the criteria for NAFLD with a complete biomarker 
dataset, with LSM available on 248. 
Biomarker distributions and agreement 
Biomarker distributions for the full study population are available in the supplementary material 
(Supplementary Figure A) and correlations between the biomarkers in Table 3 (and Supplementary Figure 
B).  After adjustment for age and sex, correlation was strong between APRI and FIB4 (r=0.92) but all others 
were ≤0.5. The inter-item correlation for all five markers was just below acceptable (α=0.67) with minimal 
improvement with the removal of any marker. Correlations were similar in the NAFLD cohort. 
Literature based cut-offs yielded marked differences in the proportions of the cohort with probable liver 
fibrosis in the full cohort: APRI 0.8%, AST/ALT ratio 22.4%, ELF 7.0%, FIB4 68.3%, and LSM 4.5%; and 
in the NAFLD subgroup: APRI 0.4%, AST/ALT ratio 16.7%, ELF 4.3%, FIB4 63.8%, and LSM 4.8%.  
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Agreement between the top 5% of the distribution for each biomarker pair was poor (Table 4). APRI and 
FIB4 had the best positive agreement at 76.4%, but agreement for all of the other biomarker pairs was 
between 9% and 32%. When the comparison groups were altered to reflect the top 3% and 7% of the 
biomarker distributions, then with the exception of APRI and FIB4, the agreement did not alter greatly 
(agreement 9-26% and 11-38% respectively).  When analyses were restricted to the study population with 
NAFLD, agreement between the top 10% of the distribution for each biomarker pair remained generally 
poor (agreement for APRI and FIB4 was 68%, all other pairs between 14% and 36%), as did agreement for 
the top 5% and 15% of the distributions (agreements from 0% to 36% and from 21% to 36% respectively, 
with exception of APRI/FIB4).  
The top 5% (10% in NAFLD) was suggestive of advanced liver dysfunction with clinical data implicating 
advanced fibrosis/cirrhosis with platelet counts being significantly lower and spleen size being significantly 
larger in the majority of cases (data not shown). 
Negative agreement (agreement on the absence of fibrosis) was more consistent for both the full cohort 
analysis and the NAFLD subgroup (90-99%) with minimal change with the alternative cut-offs described. 
2x2 tables for agreement using the top vigintiles are available in the supplementary material (Supplementary 
Table A). 
Changes in biomarkers 
Serum biomarker pairs from the year 1and year 4 follow-up were available for 534 subjects (LSM was not 
undertaken at year 1). Six patients were excluded for pre-existing liver disease leaving an analysis cohort of 
528 subjects. There were 183 (34.7%) participants fulfilling the criteria for NAFLD. 
Following a mean follow-up of 3.5 years, mean percentage (sd) changes in serum biomarkers were: 
AST/ALT ratio -0.04 (0.25), APRI 0.19 (0.37), ELF 0.03 (0.08) and FIB4 0.18 (0.30). The changes in each 
biomarker (adjusted for age and sex) were poorly correlated (AST/ALT:APRIr=0.23 p<0.001, 
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AST/ALT:ELF r=0.15 p<0.001, AST/ALT:FIB4 r=0.55 p<0.001, APRI:ELF r=0.12 p=0.008, ELF:FIB4 
r=0.13 p=0.003) with the exception of APRI and FIB4 (r=0.88, p<0.001). The results were similar when 
limited to patients with NAFLD (Supplementary Figure C). When classified as increasing, staying the same 
and decreasing, agreement remained weak (35.0% to 54.7%), again with the exception of APRI and FIB4 
(76.3% agreement). 
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Discussion 
This study is the first population based study to compare the distribution of different non-invasive markers 
of liver fibrosis in patients with type 2 diabetes.  Its strength lies in its population based approach allowing 
the results to be generalised to the wider type 2 diabetes population and not just patients at the more severe 
end of the diabetes spectrum and/or those with known fatty liver disease attending hospital clinics.  We 
found poor correlation between the five biomarkers of liver fibrosis studied. Using the top vigintile (5%) of 
each biomarker resulted in excellent agreement on the absence of advanced liver disease but poor agreement 
on the presence of advanced liver disease. 
An interesting finding of this cohort is the likely small numbers of patients with hepatic fibrosis. Based on 
strict application of validated biomarker cut offs used previously in non-diabetic populations to indicate the 
presence of fibrosis, the prevalence of significant fibrosis (Metavir F3+) appears to be between 1% and 68%, 
but is most likely less than 10%. Since NAFLD is increasingly reported as associated with type 2 diabetes, it 
is perhaps surprising (though also encouraging) to find that the prevalence of advanced liver disease may be 
low in this perceived high risk group. There are several possible reasons for a low prevalence of fibrosis in 
our study population. It may be related to specific cohort effects and survival bias, with only 'low risk' adults 
with type 2 diabetes surviving to the age of 60 years and thereby enabling participation in the study. It may 
be 'artefact', due to behaviour of the biomarkers in populations with diabetes, such that cut-points which 
indicate fibrosis in a non-diabetic person do not reflect the same level of fibrosis in a diabetic person. There 
is little literature on the distribution of biomarkers in exclusively diabetic populations, however, there are no 
clear biologically plausible reason to expect different thresholds to operate.  Thus, it may also reflect a truely 
low prevalence of fibrosis in people with diabetes.  This has not been widely studied previously, but given 
the strong association between insulin insensitivity and hepatic fibrosis development[32] it may be that the 
intensive management of diabetic patients with insulin sensitising agents (metformin[33] and peroxisome 
proliferator-activated receptor-gamma agonists (thiozolidinediones)[34])  is attenuating the development of 
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fibrosis. The probable low prevalence of fibrosis in this cohort is a limitation when analysing biomarker 
agreement and, due the well-established influence of disease prevalence on diagnostic test accuracy, it may 
be that there would be a higher biomarker agreement in populations with higher fibrosis prevalence[35]. 
In addition, 15% of LSM data was missing. The XL probe is believed to increase the success rates of 
obtaining ≥10 valid TE readings  from 56% to 75%[36] in obese populations. This is consistent with our 
85% success in a mixed overweight and obese cohort. Despite the use of the XL probe, TE still appears to be 
limited by body habitus. Those patients with missing LSM had more severe diabetes profiles and higher 
alternative biomarkers of hepatic fibrosis. Hence, it was felt necessary to expand the majority of analysis to 
those patients with a full set of biomarkers excluding LSM in order to avoid biasing the sample.  
Overall there was poor correlation between the biomarkers measured in this study. The only exception was 
APRI and FIB4 (r=0.92 in full cohort and 0.93 in NAFLD subgroup, p<0.001), which is unsurprising given 
they have a number of components in common (AST level and platelets). Assessment of inter-item 
correlation (α=0.67) determined that the five biomarkers were not consistent with each other in what they 
were measuring, with a score of α=0.70 being the minimum score usually accepted. However, a minimum of 
0.90 is often suggested for clinical practice[37]. This suggests some discrepancy in what the biomarkers are 
measuring. This seems plausible as AST/ALT, APRI and FIB4 are all similar in their composition, including 
markers of hepatocellular damage. Alternatively, ELF is measuring markers related to extracellular matrix 
turnover in fibrosis, and LSM is also examining structural properties of the liver through shear wave 
transmission.  
A higher prevalence of fibrosis in the NAFLD cohort compared to the full cohort was expected. However, 
using validated cut-offs, our results showed the opposite. This probably reflects the natural history of 
NAFLD in which fibrotic progression is often associated with steatosis regression and hence this group of 
advanced liver disease patients might not be captured by our definition of NAFLD. ELF scores and LSM 
values for the top vigintile were most in keeping with the values one would expect to find from previous 
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published studies[13-15], however, with no reference standard (biopsy) it is impossible to establish which of 
the five biomarkers is the most accurate and to comment on the true prevalence of hepatic fibrosis using 
non-invasive biomarkers.  
In addition, using validated cut-offs we found a wide range of fibrosis prevalence results for the different 
biomarkers. The reasons for the wide discrepancies are probably two-fold. Firstly, as demonstrated by the 
lack of inter-correlation, there is an inconsistency in what the different biomarkers/panels are measuring. 
Secondly, published fibrosis cut-offs from clinical validation studies do not appear to translate readily into 
research or clinical practice. The difficulty with this is that the predictive value of a test (unlike sensitivity 
and specificity) is influenced by the prevalence of underlying disease. Most validation cohorts have typically 
comprised a high proportion of patients with advanced liver disease selected from tertiary referral centres. 
Our study population has a presumed lower prevalence of advanced liver disease and consequently the 
predictive values are likely to be different. This resulting lower positive predictive value and higher negative 
predictive value would mean that literature based cut-offs are neither reliable nor directly comparable with 
one another in different patient cohorts such as ours. Without liver biopsy (the current reference standard) it 
is not possible to decide which biomarker is ‘best suited’ for diagnosing significant hepatic fibrosis in a 
lower prevalence population. 
There are numerous other panel markers of hepatic fibrosis available e.g. BARD, BAAT, NFS. These are 
typically simple scoring systems using easily available plasma results and patient data. Previous work from 
our group has found that these scores are likely to overestimate the prevalence of hepatic fibrosis in 
populations similar to ours as they rely heavily on the incorporation of impaired glucose tolerance, age and 
body mass index. For example, the prevalence of fibrosis using the BARD and BAAT scores was 92.6% and 
79.3% respectively, with the NFS predicting 16.4% fibrosis and 66.8% indeterminate[18]. It is therefore 
necessary to concentrate on the development of hepatic fibrosis markers that are independent of the 
underlying characteristics of the population under study.  
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As we observed for the cross-sectional distribution of serum biomarkers, changes in the biomarkers over 3.5 
years were also poorly correlated with the exception of the similarly derived biomarkers (APRI and FIB4). 
Even after categorising change as increasing, staying the same or decreasing, agreement remained weak. 
This is not surprising given the weak associations in cross-sectional analysis, however this may also reflect 
the short follow-up period.  
A further area which requires clarification is the most appropriate use of hepatic biomarkers in the 
general/healthy population. Without this information, it is hard to predict whether expected values are likely 
to differ in discrete populations, such as the elderly or people with diabetes. Normal routine liver function 
tests vary with age, sex and ethnicity[38, 39], and therefore any fibrosis marker panel including these 
components might benefit from specific reference ranges that reflect the individual population. 
At present, use of these non-invasive biomarkers is limited within low disease prevalence settings to 
excluding advanced liver disease. Further work is required to validate these markers for the presence of 
advanced liver disease against the liver biopsy, but more importantly to determine their predictive value for 
clinically relevant liver-related endpoints, such as hepatocellular carcinoma, oesophageal varices and 
cardiovascular outcomes, in a range of different low and high risk population groups, most notably 
community settings.  The practical and ethical challenges of large scale liver biopsy in ‘normal’ patients 
persist, but emerging techniques, such as magnetic resonance elastography[40], have the potential to become 
a more acceptable reference standard.  
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Tables 
Table 1. Characteristics of full ET2DS study population and liver biomarker analysis cohort, at 
baseline, year 1 and year 4. Values are mean (sd), median (IQR) or % (n). 
Variable Full ET2DS 
cohort at 
baseline  
(n=1066) 
Analysis cohort 
(n=767) 
Year 1 Year 4 
Age, years 67.9 (4.2) 68.7 (4.1) 71.4 (4.2) 
Sex, % male 51.3% (547) 52.8% (405) 52.8% (405) 
Fasting glucose, mmol/L 7.56 (2.1) 6.89 (2.2) 7.75 (2.9) 
HbA1c, % 7.40 (1.1) 7.19 (1.1) 7.34 (1.2) 
HbA1c, mmol/mol 57.3 (12.2) 55.1 (11.6) 56.7 (13.1) 
Duration of diabetes, years 6.71 (3.9-11.3) 7.00 (4.0-12.0) 7.10 (7.6-14.9) 
Diabetes treatment    
Diet alone, % 19.3% (193) 19.7% (144) 13.9% (106) 
OAHA alone, % 63.4% (652) 65.5% (479) 65.3% (498) 
Insulin therapy (+/- OAHA), % 17.3% (178) 14.8% (108) 20.8% (159) 
BMI, kg/m2 31.4 (5.7) 31.2 (5.6)* 31.3 (5.8) 
Total cholesterol, mmol/L 4.31 (0.9) 4.16 (0.8) 4.25 (0.9) 
HDL cholesterol, mmol/L 1.29 (0.4) 1.23 (0.3) 1.37 (0.4) 
Systolic BP,mmHg 133.3 (16.4) 138.3 (18.3) 131.4 (17.9) 
Diastolic BP,mmHg 69.1 (9.0) 74.6 (9.4) 69.1 (9.2) 
Smoking, % never 38.2% (407) 39.1% (300)* 39.1% (300) 
Platelets, x109/L 257.7 (68.9) 259.8 (67.7)* 229.8 (66.8) 
Steatosis present, % - 55.1% (423) 50.1% (384) 
ALT, U/L - 33.9 (12.8) 36.0 (11.8) 
AST/ALT ratio - 0.94 (0.3) 0.85 (0.2) 
APRI - 0.24 (0.2-0.3) 0.28 (0.2-0.4) 
ELF - 8.89 (0.8) 9.12 (0.8) 
FIB4 - 1.37 (1.1-1.8) 1.56 (1.2-2.0) 
LSM, kPa - - 5.11 (2.6) 
*Measured at baseline visit 
ALT alanine aminotransferase; APRI aspartate aminotransferase-platelet ratio index; AST aspartate 
aminotransferase; BMI body mass index; BP blood pressure; ELF European Liver Fibrosis panel; FIB4 
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Fibrosis-4 Score; HbA1c glycosylated haemoglobin; LSM liver stiffness measurement; OAHA oral anti-
hyperglycaemic agent. 
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Table 2. Association of risk factors for missing liver stiffness measures. Values are mean (sd), median 
(IQR) or % (n). 
 LSM missing 
N=119 
LSM present 
N=648 
p 
Age, years 71.2 (4.3) 71.4 (4.1) NS 
Sex, male 37.0% (44) 55.7% (361) <0.001 
Body mass index, kg/m2 35.2 (7.7) 30.6 (5.1) <0.001 
Skin capsule distance, 
cm 
2.83 (0.9) 2.32 (0.5) <0.001 
Fibroscan probe, ‘M’ 42.0% (50) 65.6% (425) <0.001 
Glucose, mmol/L 8.21 (3.4) 7.66 (2.8) NS 
HbA1c, % 7.54 (1.3) 7.30 (1.2) 
0.038 
HbA1c, mmol/mol 59.0 (14.2) 56.3 (12.9) 
ALT, U/L 36.6 (13.2) 35.8 (11.5) NS 
AST, U/L 31.3 (12.2) 29.3 (9.9) NS 
GGT, U/L 19.0 (12.0-48.5) 16.0 (9.5-27.0) 0.001 
AST/ALT ratio 0.88 (0.3) 0.85 (0.2) NS 
APRI 0.30 (0.21-0.44) 0.28 (0.21-0.37) NS 
ELF 9.37 (1.0) 9.08 (0.8) 0.002 
FIB4 1.65 (1.21-2.30) 1.55 (1.22-1.96) NS 
ALT alanine aminotransferase; APRI aspartate aminotransferase-platelet ratio index; AST aspartate 
aminotransferase; ELF European Liver Fibrosis panel; FIB4 Fibrosis-4 Score; GGT gamma-glutamyl 
transferase; HbA1c glycosylated haemoglobin. 
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Table 3. Correlations between biomarkers. Values are correlation coefficients, adjusted for age and 
sex 
Table 3A. Full cohort (n=767)  Table 3B. NAFL cohort (n=282) 
APRI r=0.30     APRI r=0.32    
ELF r=0.24 r=0.31    ELF r=0.18 r=0.32   
FIB4 r=0.53 r=0.92 r=0.30   FIB4 r=0.53 r=0.93 r=0.29  
LSMa r=0.15 r=0.20 r=0.25 r=0.16  LSMb r=0.15 r=0.29 r=0.26 r=0.29 
 AST/ALT APRI ELF FIB4   AST/ALT APRI ELF FIB4 
a n=648  
b n=248 
All p<0.001 
APRI aspartate aminotransferase-platelet ratio index; AST/ALT aspartate aminotransferase-alanine 
aminotransferase ratio; ELF European Liver Fibrosis panel; FIB4 Fibrosis-4 Score; LSM liver stiffness 
measure.  
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Table 4. Agreement between biomarker pairs for the top 5 or 10% of values, in the full cohort and 
NAFL subgroup. 
Table 4A. Positive agreement (presence of fibrosis) in the top 5% of the full cohort. 
APRI 18.4%     
ELF 18.4% 31.6%    
FIB4 34.2% 76.3% 34.2%   
LSM 9.5% 12.7% 15.9% 12.7%  
 AST/ALT APRI ELF FIB4  
      
Table 4B. Negative agreement (absence of fibrosis) in the bottom 95% of the full cohort. 
APRI 95.7%     
ELF 95.7% 96.4%    
FIB4 96.6% 98.8% 91.8%   
LSM 95.4% 95.5% 95.7% 95.5%  
 AST/ALT APRI ELF FIB4  
 
Table 4C. Positive agreement (presence of fibrosis) in the top 10% of the NAFL subgroup. 
APRI 28.6%     
ELF 14.3% 28.6%    
FIB4 35.7% 67.9% 32.1%   
LSM 29.2% 20.8% 25.0% 25.0%  
 AST/ALT APRI ELF FIB4  
      
Table 4D. Negative agreement (absence of fibrosis) in the bottom 90% of the NAFL 
subgroup. 
APRI 92.1%     
ELF 90.6% 92.1%    
FIB4 92.9% 96.5% 92.5%   
LSM 92.4% 91.5% 9.9% 91.9%  
 AST/ALT APRI ELF FIB4  
APRI aspartate aminotransferase-platelet ratio index; AST/ALT aspartate aminotransferase-alanine 
aminotransferase ratio; ELF European Liver Fibrosis panel; FIB4 Fibrosis-4 Score; LSM liver stiffness 
measure.  
  
